Compare CFR & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFR | CRL |
|---|---|---|
| Founded | 1868 | 1947 |
| Country | United States | United States |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.5B |
| IPO Year | N/A | 1999 |
| Metric | CFR | CRL |
|---|---|---|
| Price | $135.72 | $160.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $143.08 | ★ $200.09 |
| AVG Volume (30 Days) | 479.1K | ★ 733.7K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $9.72 | $0.99 |
| Revenue Next Year | $4.70 | $3.26 |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $100.31 | $91.86 |
| 52 Week High | $148.97 | $228.88 |
| Indicator | CFR | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 44.40 |
| Support Level | $134.54 | $158.36 |
| Resistance Level | $140.27 | $166.62 |
| Average True Range (ATR) | 2.76 | 6.77 |
| MACD | 0.49 | 1.36 |
| Stochastic Oscillator | 78.25 | 52.98 |
Cullen/Frost is a regional US bank with around $53 billion in assets (as of December 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.